First Approved Treatment for Desmoid Tumors in Europe

We are pleased to share some very encouraging news for the desmoid tumor community. On August 18, 2025, the European Commission (EC) approved nirogacestat (OGSIVEO®) for adults with progressing desmoid tumors who need systemic treatment.
This is the first-ever treatment officially approved in Europe for desmoid tumors — an important milestone that brings new hope to patients, families, and clinicians.

Desmoid tumors are rare and locally aggressive. They don’t spread to other parts of the body, but they can be very difficult to manage, often causing pain, fatigue, and limitations in daily life. Until now, there were no approved medicines available in Europe.
This approval marks a long-awaited step forward and a reason for hope for our community.